{"organizations": [], "uuid": "431963576437f869855fd884c53dbfdf25ed78ec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-haemonetics-corp-qtrly-revenue-234/brief-haemonetics-corp-qtrly-revenue-234-0-million-idUSFWN1PW0IS", "country": "US", "domain_rank": 408, "title": "BRIEF-Haemonetics Corp Qtrly Revenue $234.0 Million", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T13:36:00.000+02:00", "replies_count": 0, "uuid": "431963576437f869855fd884c53dbfdf25ed78ec"}, "author": "", "url": "https://www.reuters.com/article/brief-haemonetics-corp-qtrly-revenue-234/brief-haemonetics-corp-qtrly-revenue-234-0-million-idUSFWN1PW0IS", "ord_in_thread": 0, "title": "BRIEF-Haemonetics Corp Qtrly Revenue $234.0 Million", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-haemonetics corp", "sentiment": "negative"}, {"name": "haemonetics corp", "sentiment": "none"}, {"name": "haemonetics", "sentiment": "none"}, {"name": "thomson", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 6, 2018 / 11:38 AM / in 2 minutes BRIEF-Haemonetics Corp Qtrly Revenue $234.0 Million Reuters Staff \nFeb 6 (Reuters) - Haemonetics Corp: * QTRLY REVENUE OF $234.0 MILLION WAS UP 2.7 PCT‍​ \n* QTRLY ADJUSTED EARNINGS PER SHARE $0.62; QTRLY LOSS PER SHARE $0.12 \n* BOARD OF DIRECTORS AUTHORIZES $260 MILLION SHARE REPURCHASE PROGRAM‍​ \n* INCURRED $31.3 MILLION OF RESTRUCTURING AND TURNAROUND COSTS IN QUARTER * SEES FISCAL 2018 GAAP EARNINGS PER SHARE $.80 - $.85 \n* SEES FISCAL 2018 ADJUSTED EARNINGS PER SHARE $1.80 - $1.90 \n* SEES FISCAL 2018 FREE CASH FLOW, BEFORE RESTRUCTURING & TURNAROUND OF ABOUT $125 MILLION * SEES FISCAL 2018 CAPITAL EXPENDITURES $40 - 50 MILLION \n* HAEMONETICS- COMPLEXITY REDUCTION INITIATIVE EXPECTED TO DELIVER $80 MILLION IN ANNUAL RUN RATE SAVINGS; SAVINGS ARE EXPECTED TO BE MINIMAL IN FISCAL 2018 \n* Q3 EARNINGS PER SHARE VIEW $0.44, REVENUE VIEW $227.6 MILLION -- THOMSON REUTERS I/B/E/S \n* EXPECTS TO INCUR AGGREGATE RESTRUCTURING CHARGES OF $50-$60 MILLION TO COMPLETE COMPLEXITY REDUCTION INITIATIVE \n* FY2018 EARNINGS PER SHARE VIEW $1.70 -- THOMSON REUTERS I/B/E/S Source text for Eikon: ( bit.ly/2FRec83 ) Further company coverage:", "external_links": [], "published": "2018-02-06T13:36:00.000+02:00", "crawled": "2018-02-06T13:43:30.001+02:00", "highlightTitle": ""}